JCO:HER2 dual targeted therapy significantly improves prognostication in breast cancer patients.

The CALGB 40601 trial was designed to assess whether the use of dual and single-drug target human skin growth factor 2 (HER2) in new complementary chemotherapy improved pathological complete remission (pCR).
this report analyzed no re-occurrence rates (RFS) and total survival rates (OS), as well as gene expression signatures that predict pCR and survival rates.
In the CALGB 40601 trial, 350 untreated stage II-III HER2-positive breast cancer patients were randomly assigned to three groups to receive treatment of yew alcohol-combined cytoproquine-lapatini (THL), yew alcohol combined monoantigen (TH) or yew alcohol-combined rapatinib (TL).
end point is pCR, and secondary nodes include RFS, OS, and gene expression analysis.
mRNA sequencing of 264 pre-treated samples.
180 patients were asserted to the TL group, 120 to the TH group and 67 to the TL group.
more than 7 years of follow-up, RFS and OS were significantly better in patients in the THL group than in the TH group (RFS risk ratio of 0.32; OS risk ratio of 0.34), and there was no significant difference between the TH group and the TL group.
of the 688 previously described gene expression signatures, 215 were associated with pCR, 45 months of RFS, and only 22 were associated with pCR and RFS (3.2 percent).
, eight immune characteristics were significantly associated with higher pCR rates and better RFS.
in patients with positive residual lesions, immunoglobulin G characteristics were independent good prognostic factors, while HER2 rich characteristics associated with higher pCR rates were associated with significantly shorter RFS.
in the CALGB 40601 trial, dual-target HER2 therapy significantly improved RFS and OS.
insidian subsype and immunomarking characteristics make it possible to predict pCR and RFS, both in general and in residual disease groups.
study may guide a reasonable treatment strategy for her2-positive breast cancer.
.